WEEK OF OCTOBER 31, 2022
The Future of Precision and Predictive Health Care
Japan Healthcare Week, featuring Conference Events in Tokyo (Oct. 31) and Awajishima (Nov. 2)
Japan Week Event on November 2nd, 2022
Japan Week 2022 | Meet American and Japanese Companies
Awajishima Healthcare Forum
Nov 2nd, 2022
10:00 AM–6:00 PM (JT)
Followed by Networking Reception
Awajishima Healthcare Forum:
Awaji Yumebutai International Conference Center Link
Chief Executive Officer,
Fogarty Innovation
Andrew Cleeland is the CEO of Fogarty Innovation. A seasoned executive with more than 30 years of experience in the medical device industry, he has held key leadership positions in organizations ranging from early–stage start–ups to large multinationals.
9:00 A.M. – 10:00 A.M.
REGISTRATION
10:00 A.M. – 10:30 A.M.
WELCOME AND OVERVIEW OF THE FORUM
10:30 A.M. – 11:15 A.M.
KEYNOTE SPEECH: INNOVATION FOR THE FUTURE OF PREDICTIVE HEALTHCARE
Andrew Cleeland is the CEO of Fogarty Innovation. A seasoned executive with more than 30 years of experience in the medical device industry, he has held key leadership positions in organizations ranging from early–stage start–ups to large multinationals.
11:15 A.M. – 12:10 P.M.
SESSION 1: PREDICTIVE HEALTHCARE PROGRAMS AND SUPPORT FROM US & JAPAN – INCUBATORS/ACCELERATORS AND AN INTERNATIONAL ECOSYSTEM
After graduating from Jichi Medical University, he began practicing general medicine in the rural areas of Japan. Fumiaki joined the Department of Cardiovascular Medicine at Stanford University in 2001, and was closely involved with the R&D, animal studies, and clinical studies of many medical device startups. He is also actively involved in projects with the US and Japanese regulatory agencies working to create an effective cross-border medical device eco-system. Fumiaki has also been an advisory faculty for the Stanford Biodesign Program since 2014. He is deeply involved with the development of the Japan Biodesign Program and is working diligently to establish a Silicon Valley-like medical device eco-system in Japan.
Andrew Cleeland is the CEO of Fogarty Innovation. A seasoned executive with more than 30 years of experience in the medical device industry, he has held key leadership positions in organizations ranging from early–stage start–ups to large multinationals.
He received the B.S. degree, the M.S. degree in information and communication engineering, and the Ph.D. degree in electronic engineering, all from the University of Tokyo, in 1998, 2000, and 2003, respectively. From Apr. 2003 to Jun. 2006, he was an assistant professor at Department of Orthodontics and Dentofacial Orthopedics, Graduate School of Dentistry, Osaka University. He became a lecturer at Department of Orthodontics and Dentofacial Orthopedics, Osaka University Dental Hospital in Jul. 2006.
[Current position]
Specially Appointed Professor, Co-Creation Organization, Osaka University
Invited Professor, Cybermedia Center, Osaka University
Visiting Professor, Tokushima University Research Support and Industry-Academia-Government Collaboration Promotion Department
Director, NPO Information Chemistry and Biology Society (CBI Society CBI Research Organization Next Generation Modality Research Institute)
12:10 P.M. – 12:30 P.M.
LUNCH BREAK
12:30 P.M. – 1:00 P.M.
LUNCH BREAK PRESENTATIONS
1:00 P.M. – 1:30 P.M.
SPECIAL SESSION: AWAJISHIMA, THE WELL-BEING ISLAND
1:30 P.M. – 2:25 P.M.
SESSION 2: PREDICTIVE & PROACTIVE HEALTHCARE NEEDS – DEVICES, DRUGS, BIOTECH, SUPPORT HARDWARE AND SOFTWARE – DIAGNOSTICS, THERAPIES, ROBOTICS, BIOMARKERS
Ryan has spent 35 years in the Life Sciences and Medical Device industries focusing on innovation and adding value to the companies that drive it. He has worked with numerous companies that have invented novel technologies for a range of markets, including cell and gene therapies, biotherapeutics, biotech instrumentation, in vitro diagnostics, and medical devices. At Triple Ring Technologies, Ryan leads teams of world class scientists and engineers who work at the intersection of patient needs and cutting-edge technology development.
David Case is a highly experienced intellectual property and venture capital transactions attorney admitted in the States of California, New York, Washington and Oregon. Prior to starting his own firm near Silicon Valley, David spent 20+ years as an associate and later equity partner at two different 1st tier international law firms practicing in New York City, Tokyo and Silicon Valley. David’s practice has a particular emphasis on life sciences and medical devices.
Dr. Burnett is a veteran in the medical device industry having founded many successful companies at various stages. During his undergraduate career at the University of Pennsylvania, he focused on bioengineering and spent a year at the Food and Drug Administration both testing devices and writing congressional reports on the current state-of-the-art devices.
Dean has over 25 years of experience in launching and growing brands in the areas of: medical devices, OTC health/wellness products, digital health apps, medical/pharmaceutical therapeutics, life science start-ups as well as Fortune 25 companies. Dean is currently the Chief Commercial Officer of Intuity Medical Inc., a Silicon Valley MedTech company launching a highly disruptive glucose meter in the diabetes industry.
2:25 P.M. – 2:35 P.M.
BREAK
2:35 P.M. – 3:25 P.M.
SESSION 3: DIGITAL HEALTH, ARTIFICIAL INTELLIGENCE, AND DIGITAL TWINS IN PREDICTIVE HEALTHCARE
Mika is a commercialization executive with extensive leadership experience in conceiving, planning, and launching disruptive medical technologies in 50 markets across North America, EMEA, Asia-Pacific, and Latin America. She has an exceptional track record of leading businesses from inception to across different clinical segments, including cardiovascular, fertility, and oncology.
Partha Ray is a mission-driven medtech innovation leader with over 25 years of deal & operating experience at leading global organizations. Partha has launched products and closed deals which benefit over 9M patients and generate over $20B/yr in revenues today.
In April of 2021, Iori Sumida moved to Accuray, Japan from Osaka University. Based on the clinical experience in medical physics he gained over 18 years, he currently works as the Senior Director to bring growth to the company from the marketing, physics, and clinical support aspects. His major skill is to develop artificial intelligence in radiation therapy and has been proved in the textbook published from the IOP.
Founder and CEO of EchoPixel, a startup company pioneering medical imaging VR/AR solutions that are defining a new visualization paradigm Holographic Therapy Guidance (HTG), which allows doctors to perform minimally invasive surgeries using a digital twin of the patient that they experience as a hologram.
Rob creates new businesses that address the unmet needs of patients, doctors, innovators and authorities. He is passionate about developing creative solutions for access to Japan’s healthcare market.
3:25 P.M. – 3:30 P.M.
BREAK
3:30 P.M. – 4:20 P.M.
SESSION 4: PREDICTIVE HEALTHCARE TARGETS – MENTAL HEALTH, COGNITIVE DISEASES, HOSPICE, CANCER, CARDIAC DISEASES, METABOLIC DISEASES, ICU, DIALYSIS, STROKE
Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. Elton represents both public and private enterprises as their outside general counsel and serves as a key strategic advisor from their inception throughout their life cycle. He advises on complex venture capital and corporate finance transactions, corporate law and governance, mergers and acquisitions, and public offerings.
He is a seasoned data scientist and previously served as the Chief Data Officer at a Japanese fin-tech startup, AnyPay and an AI OCR solution provider, AI inside. He and his co-founders founded ALY Inc. to accelerate DX and data usage in the healthcare/medical domain. He received his B.S. from UC Berkeley and M.S. in Data Science from GalvanizeU San Francisco.
Seasoned consultant in life sciences & healthcare industries with in-depth understanding of science, technologies, and commercial-side logics. Serves global and Japanese leading players in pharmaceutical, medical devices, medical ICT, life insurances, chemical/food/beverage companies, general trading companies, PEs, and startups (biotech/medtech/healthtech).
Tomoyasu Muto (“Mutoo”) is Director, Health Management IT of SoftBank Corp, leading strategic investment and business development for innovative healthcare systems. Valuation of New Therapy has been the primary interest at work, helping corporates appraise and communicate true benefit of innovative modalities at consideration.
4:20 P.M. – 5:40 P.M.
PRIVATE COMPANY PRESENTATIONS
Alan Raby is the CEO and Founder of CareMates, a digital care platform for older adults.
Alan has over 30 years of experience in which 20+ years have been spent working in the technology industry globally. He is a serial entrepreneur and intrapreneur. He has ~ 20 years of experience working in Japan and was previously a General Manager with SONY where he was responsible for bringing SONY FeliCa technology, EDY e-money and Osaifu-Keitai from Japan to the US. He is a pioneer in FinTech and launched the first nation wide mobile banking application in the US in 2001.
Founder and CEO of EchoPixel, a startup company pioneering medical imaging VR/AR solutions that are defining a new visualization paradigm Holographic Therapy Guidance (HTG), which allows doctors to perform minimally invasive surgeries using a digital twin of the patient that they experience as a hologram.
Mr. Lichorowic is a highly accomplished serial entrepreneur and chief executive in the field of high tech and medical industries. Starting off in Fortune 500 companies in high tech in Silicon Valley, Mr. Lichorowic crossed into the medical field and now leverages twenty-five years of expertise in big data, machine learning, AR & amp; VR and surgical robotics.
Dean has over 25 years of experience in launching and growing brands in the areas of: medical devices, OTC health/wellness products, digital health apps, medical/pharmaceutical therapeutics, life science start-ups as well as Fortune 25 companies. Dean is currently the Chief Commercial Officer of Intuity Medical Inc., a Silicon Valley MedTech company launching a highly disruptive glucose meter in the diabetes industry.
Jerome has over 30 years of commercial experience in the life science and biotechnology industry in various sales, marketing, and business development roles. His contributions have helped 3 startup companies achieve profitability. He has also held management positions in global organizations such as Becton Dickinson and GE Healthcare. Jerome has a BS in Biochemistry and Cell Biology from the University of California, San Diego and an MBA from San Diego State University.
Shungo ADACHI, Co-founder and Representative Director, has more than 15 years of experience in innovative healthcare management and policy development in Japan and overseas. He has had overall management responsibility for medical cluster projects, working with corporations and providing strategic planning for R&D and operations teams.
David Lapointe
David currently serves as CEO of Optina Diagnostics. Optina’s Retinal Deep Phenotyping platformTM, with the first indication of development being the diagnosis of Alzheimer’s disease, offers non-invasive and more accessible tests. With an early and accurate diagnosis, physicians, patients, and caregivers will have better planning and early treatment options, making the patient journey much easier.
Luiz Augusto (Guto) de Castro e Paula
Guto is the Director of Innovation and Partnerships at Optina Diagnostics, responsible for strategic partnering and working with pharma industry and academic customers. Before taking this role, Guto was the Business Unit Director of Computed Tomography and Molecular Imaging for GE Healthcare for 7 years, where he also held other leadership roles in product and sales for a total of 14 years in that company.
Charles Cielo oversees Intralink’s Life Sciences practice in Japan, helping overseas companies – including Personalis – navigate market entry and find their place in the unique Japanese healthcare ecosystem. A bioengineer by training, scientist by vocation and businessman by trade, he’s proficient in three languages and worked for global big pharma prior to joining Intralink.
5:40 P.M. – 5:50 P.M.
CLOSING REMARKS
6:00 P.M. – 7:00 P.M.
SOCIAL NETWORKING
